A single ‐center, open‐label, randomized cross‐over study to evaluate the pharmacokinetics and bioavailability of once‐daily prolonged‐release formulations of tacrolimus in de novo liver transplant recipients

ConclusionDespite methodological weaknesses that limit the conclusions, we have found a more consistent drug exposure for LCP-Tac in de novo LT recipients. LCP-Tac demonstrated a greater bioavailability compared to PR-Tac.

Source: Immunity, Inflammation and Disease - September 24, 2021 Category: Allergy & Immunology Authors: Uta Herden, Martina Sterneck, Bettina M. Buchholz, Eike G. Achilles, Armin Ott, Lutz Fischer Tags: ORIGINAL ARTICLE Source Type: research